InflaRx Maps Out Izicopan AAV Strategy: Two Phase 2 Trials in 2027, $1.5-2.0B Peak Sales Target
IFRX sits 98% above its 52-week low of $0.798 on elevated volume (6.8× avg).
Summary
At its Capital Markets Day, InflaRx said it will start two Phase 2 trials of oral izicopan in ANCA-associated vasculitis in 2027, with first data in 2028, and cited an independent estimate of $1.5-2.0 billion in peak sales. Cash of €153.3 million at September 30, 2026 is expected to fund operations through 2029.
Key Events · Product Development and Regulatory · IFRX
-
Two Phase 2 AAV Trials Planned for 2027
A randomized, double-blind, placebo-controlled Phase 2 in AAV with renal involvement (~35 patients per arm, 1:1:1, 24-week key efficacy endpoint, ~18-month enrollment) plus an open-label two-stage Phase 2 (~30 patients) testing glucocorticoid replacement. Site initiation is expected in early 2027, with first data in 2028.
-
Peak Sales Potential Put at $1.5-2.0 Billion
InflaRx cites an independent commercial assessment (October 2026) for izicopan in AAV, with a base case of $1.65 billion in global peak net sales. This is a third-party forward-looking estimate, not company guidance.
-
Cash Funds Operations Through 2029
Cash, cash equivalents and marketable securities totaled €153.3 million at September 30, 2026, which the company expects to fund ongoing operations and clinical development through 2029.
-
Advisory Board Formed for AAV and Renal Disease
Seven named international experts in vasculitis, nephrology and immune-mediated kidney disease will advise on disease biology, clinical development and the treatment landscape.
Analysis · IFRX · Life Sciences
The Capital Markets Day gave the izicopan story a concrete shape: two Phase 2 AAV trials starting in 2027, first data in 2028, and an independent assessment pegging peak net sales at $1.5-2.0 billion. That is the number investors will now anchor on, and it dwarfs a market value that is a fraction of it — so the disclosure reframes izicopan from an early asset into a defined, funded program. With €153.3 million on hand at September 30, 2026, and runway stated through 2029, the plan is paid for without an immediate raise. Timing is the catch: no efficacy readout until 2028, so nothing here resolves the clinical question soon, and the peak-sales figure is a third-party estimate, not guidance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IFRX was trading at $1.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238.7M. The 52-week trading range was $0.80 to $2.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.